Skip to main content
Premium Trial:

Request an Annual Quote

CeMines Opens New Division in Estonia

NEW YORK, Dec. 3 (GenomeWeb News) - CeMines has created a new operating division in Estonia called CeMines International, which will become a wholly owned subsidiary of CeMines, the company said today.


In Estonia, CeMines will "expand [its] research-and-development initiatives, establish a regulatory-affairs presence in the European Union and accelerate commercialization of new methods and technology," according to CEO Roger Attick.


"A comprehensive international business strategy is central to long-term competitive advantages," Attick added. CeMines will also leverage its presence in Europeto cultivate new research partnerships and distribution channels."


CeMines, based in Golden, Colo., is developing its molecular fingerprinting technologies for early-stage diagnostics and therapeutics.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.